AMSilk GmbH – the world’s first industrial supplier of bio-fabricated silk protein materials – announced it has successfully raised an additional €25 million in an extended Series C funding round led by existing investor ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. And AMSilk’s outstanding technology platform – based on silk proteins – produces bio-fabricated materials that can be utilized across a variety of applications such as textile fibers, medical devices, and consumer goods.
AMSilk’s unique bio-fabrication essentially reprograms microorganisms to enable them to produce silk proteins into usable forms such as powders, hydrogels, fibers, and coatings. When combined with its unique fermentation process, this enables the company to produce complex proteins in large quantities for various market segments including textiles, medical use or consumer goods. AMSilk’s bio-fabricated silk materials are 100% protein, fully biodegradable, and do not include any source of microplastics
Since the successful €29 million financing in 2021, the company has invested in partnership agreements with world-leading brands in the apparel, medical and automotive industry, and supply contracts with leaders from the biotech industry.
What the funding will be used for: The proceeds from the financing will enable AMSilk to accelerate the ongoing scale-up of its industrialization and commercialization projects worldwide to meet the ever-increasing demand for AMSilk’s innovative materials.
KEY QUOTES;
“We are delighted to have closed this successful financing round which validates our technology and underpins our ongoing development as we scale-up and expand our commercial operations. We will invest in technology to ensure that we continue to provide innovative, attractive solutions to our customers, and improve the commercial supply of our products to expand our business.”
— Ulrich Scherbel, Chief Executive Officer of AMSilk
“This fundraising is a significant step to accelerate the upscaling of AMSilk. This will now create the capabilities to produce in large volumes and meet the high demand growth from our customers, enabling them to create sustainable products in harmony with nature.”
— Dr Wolfgang Colberg, Chairman of the Advisory Board
“ATHOS has been investing in revolutionary technologies ever since. We are highly interested in bio-materials, because of their proven ability to change the world for the better. As one of the founding investors, we continue to support AMSilk in this important step to scale up its production. AMSilk’s game-changing products can have a real impact on the market.”
— Daniel Kolb, Investment Manager at ATHOS KG
